Apixaban (Eliquis) for DVT Prophylaxis After Hip or Knee Replacement
For DVT prophylaxis after total hip or knee replacement, use apixaban 2.5 mg orally twice daily, starting 12-24 hours post-surgery, for 35 days after hip replacement and 12 days after knee replacement. 1, 2
Dosing Regimen
Standard dose: Apixaban 2.5 mg orally twice daily 1, 2
Timing of initiation: 12-24 hours after wound closure 3, 2
Duration:
This regimen is FDA-approved and supported by the most recent 2025 and 2026 guidelines 1, 4. The ADVANCE-2 and ADVANCE-3 trials demonstrated that apixaban was superior to enoxaparin 40 mg daily for VTE prevention, with lower bleeding rates 3. In hip replacement (ADVANCE-3), VTE occurred in 1.4% with apixaban versus 3.9% with enoxaparin (RR 0.36, P<0.001) 5. In knee replacement (ADVANCE-2), VTE occurred in 15% with apixaban versus 24% with enoxaparin (RR 0.62, P<0.0001) 6.
Contraindications and Precautions
Absolute contraindications: 1
- Creatinine clearance <25 mL/min
- Mechanical prosthetic heart valves
- Moderate to severe mitral stenosis
- Pregnancy and breastfeeding
- Child-Pugh C liver disease
- High-risk antiphospholipid syndrome (triple positive, history of arterial thrombosis)
Drug interactions requiring avoidance:
- Potent CYP3A4 inhibitors (ketoconazole, ritonavir) 3
- These increase plasma concentrations and are contraindicated
Renal dosing: No dose adjustment needed for CrCl ≥25 mL/min 1. Use is not recommended below this threshold.
Perioperative Management
If surgery is delayed or interrupted:
- Stop apixaban at least 48 hours before elective procedures with moderate-to-high bleeding risk 2
- Stop at least 24 hours before procedures with low bleeding risk 2
- Bridging anticoagulation is not required during the 24-48 hour interruption 2
Resumption after procedures:
- Restart when adequate hemostasis is established 2
- For low bleeding risk surgery: resume 24 hours postoperatively 7
- For high bleeding risk surgery: resume 48-72 hours postoperatively, consider reduced dose (2.5 mg once daily initially) 7
Alternative Agents
The 2026 ACC guidelines note that both DOACs and LMWH are appropriate for VTE prophylaxis post-THA/TKA 4. The American Society of Hematology 2019 guidelines recommend DOACs over LMWH primarily due to easier logistics and cost-effectiveness 4.
Alternatives include:
- Rivaroxaban: 10 mg daily for 35 days (hip) or 10-14 days (knee) 1
- Enoxaparin: 40 mg subcutaneously daily (European regimen) or 30 mg twice daily (North American regimen) 3
- Dabigatran: 110 mg 1-4 hours post-surgery, then 220 mg once daily 1
- Aspirin: Increasingly used but requires validation in multicenter trials 8
Important caveat: Recent observational data suggests apixaban may be associated with increased odds of VTE and bleeding complications compared to aspirin 9, though this contradicts RCT evidence. The ADVANCE-1 trial failed to meet noninferiority criteria versus enoxaparin 30 mg twice daily 10, highlighting that efficacy may vary with comparator regimen.
Clinical Pearls
- Apixaban does not require routine laboratory monitoring 1
- For life-threatening bleeding, use andexanet alfa for reversal 1
- If andexanet unavailable, consider prothrombin complex concentrates 1
- Monitor renal function postoperatively if surgery could affect kidney function 11
- The 2026 ACC statement emphasizes that DOACs should not be used for hip fracture surgery—LMWH remains preferred 4